🇺🇸·19h agoResearch
NCT07607678: A Study in People With Advanced Cancer to Test How Well Different Doses of BI 3819026 Are Tolerated When Taken Alone and Together With Ezabenlimab
Study type: INTERVENTIONAL. Phase: PHASE1.
Publisher
C
ClinicalTrials.gov
USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- ClinicalTrials.gov
- Region
- USA
- Scope
- Research
- Published
- July 22, 2026
- Language
- EN
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
Study type: INTERVENTIONAL. Phase: PHASE1.
Source route
Continue on clinicaltrials.gov
Leave the platform to read the original full article on the publisher site.
Source: ClinicalTrials.gov
Scope: Research
Related coverage
More related coverage
UNC Chapel Hill/4h ago
Susan Ehringhaus, Carolina’s first University counsel, dies at 82
Women's College Hospital/4h ago
Dr. Cynthia Maxwell Receives the 2026 SOGC Mentorship Award
Genome Canada/4h ago
Genome Canada appoints new Board members and SIAC Chair
UNC Chapel Hill/5h ago